Oncotarget Aims to Treat Drug-Resistant Breast Cancer
Researchers at Oncotarget have discovered a potential way to make treatment more effective in an aggressive type of breast cancer that effects 15 percent of patients known as triple negative breast cancer (TNBC). Currently, hormone based therapy is essentially ineffective in TNBC as the cancerous cells lack the hormone receptors needed to bind the medications. This has left the disease essentially un-treatable with this method, leaving patients with a rather poor prognosis. Follow Oncotarget on Twitter.
Oncotarget’s research has identified a potential cellular modification that could change everything for the treatment of this disease. They found by grafting a secondary estrogen receptor to the cancerous cells in the lab model, the hormone based treatments became effective and the tumor growth slowed and even regressed in some cases. This discovery could potentially make treatment and a TNBC future within our reach. Watch this video on Youtube.
Oncotarget has also recently awarded 4 international biomedical researchers grants at 2017’s Frontiers in Cancer Science conference held in Singapore November 6-8th by 7 prestigious research institutes. The grants were awarded to presenters on topics ranging from renal cancer to asbestos related tumors and their resistance to treatment. Oncotarget is committed to learning more about every type of cancer to advance research in different areas of the disease.
These grants will allow for travel opportunities for the researchers and their teams to ensure that they have access to the locations and people they need. The Frontiers in Cancer Science conference brings together experts in the field of cancer science and with the assistance of Oncotarget, they will continue to be able to do so.